CCCC – c4 therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Clinical trial results drove insider trading: SEC [Investment Executive - News]
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Form 4 C4 Therapeutics, Inc. For: Jan 16 Filed by: REYNO LEONARD
Form 8-K C4 Therapeutics, Inc. For: Jan 14
Form 4 C4 Therapeutics, Inc. For: Jan 02 Filed by: Anderson Kenneth Carl
Form 4 C4 Therapeutics, Inc. For: Jan 02 Filed by: GROGAN DONNA ROY
Form EFFECT C4 Therapeutics, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.